# US 2014/0350257 A1 · Process for the Preparation of a DPP-IV Inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0350257 A1
- Document ID: US20140350257A1
- Status: Published application
- Kind: A1
- Application number: 14/323,021
- Filed: 2014-07-03
- Published: 2014-11-27
- Earliest claimed: 2007-08-30
- Assignees: Hoffmann-La Roche Inc.
- Applicants: Hoffmann-La Roche Inc.
- Inventors: Ulrike Bromberger; Ralph Diodone; Stefan Hildbrand; Roland Meier
- Web page: https://patentgrep.com/patent/US20140350257A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/12: Antihypertensives
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention is concerned with an improved process for the preparation of pyrido[2,1-a]isoquinoline derivatives of formula I wherein R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by lower alkoxycarbonyl, aryl or heterocyclyl, and the pharmaceutically acceptable salts thereof. The invention also relates to two crystalline forms of (2S,3S,11bS)-1-(2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl)-4(S)-fluoromethyl-pyrrolidin-2-one dihydrochloride, which are form A and form B and to an amorphous form of said compound.

## Claims

### Claim 1

A process for the preparation of a pyrido[2,1-a]isoquinoline derivative of formula I
wherein R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by lower alkoxycarbonyl, aryl or heterocyclyl, and pharmaceutically acceptable salts thereof,
comprising the deprotection of an N-protected pyrido[2,1-a]isoquinoline derivative of formula II
wherein R1, R2 and R3 are as defined above and R4 is an amino protecting group,
with hydrochloric acid in a solvent selected from the group consisting of an aliphatic ketone, an aliphatic nitrile, a cyclic ether or mixtures thereof, and water in admixture with an aliphatic ketone, an aliphatic nitrile, a cyclic ether or mixtures thereof.

### Claim 2 (depends on 1)

The process according to claim 1, characterized in that the solvent is selected from the group consisting of acetone, methyl ethyl ketone, acetonitrile, tetrahydrofuran or mixtures thereof, and water in admixture with acetone, methyl ethyl ketone, acetonitrile, tetrahydrofuran or mixtures thereof.

### Claim 3 (depends on 1)

The process according to claim 1, characterized in that acetone or tetrahydrofuran or mixtures thereof, or water in admixture with acetone or tetrahydrofuran or mixtures thereof are used.

### Claim 4 (depends on 1)

The process according to claim 1, wherein R1 and R2 are methoxy and R3 is hydrogen.

### Claim 5 (depends on 1)

The process according to claim 1, further comprising
a) coupling an amine of formula III
wherein R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by lower alkoxycarbonyl, aryl or heterocyclyl, and R4 is an amino protecting group, with the fluorolactone of the formula IV
in the presence of 6-chloropyridin-2-ol as catalyst to form the butyramide of the formula V
wherein R1, R2, R3 and R4 are as defined above;
b) forming the mesylate of formula VI
wherein R1, R2, R3 and R4 are as defined above and Ms stands for methanesulfonyl, by reacting the butyramide of formula V with methanesulfonyl chloride or methanesulfonyl anhydride;
c) ring closing of the mesylate of formula VI in the presence of an organic base to form the N-protected pyrido[2,1-a]isoquinoline derivative of formula II
wherein R1, R2 and R3 are as defined above and R4 is an amino protecting group and
d) deprotecting the N-protected pyrido[2,1-a]isoquinoline derivative of formula II with hydrochloric acid in a solvent selected from the group consisting of an aliphatic ketone, an aliphatic nitrile, a cyclic ether or mixtures thereof, and water in admixture with an aliphatic ketone, an aliphatic nitrile, a cyclic ether or mixtures thereof.

### Claim 6 (depends on 5)

The process according to claim 5, characterized in that in step a) the 6-chloropyridin-2-ol catalyst is applied in an amount of 0.05 mol equivalents to 0.20 mol equivalents relating to one mol equivalent of the amine of formula III.

### Claim 7 (depends on 5, 6)

The process according to claim 5 or 6, characterized in that the conversion in step a) is performed at a temperature of 80° C. to 111° C.

### Claim 8 (depends on 5)

The process according to claim 5, characterized in that the butyramide of formula V obtained from step a) is used for the mesylation step b) without isolation from the reaction mixture.

### Claim 9 (depends on 5)

The process according to claim 5, characterized in that in step b) methanesulfonyl chloride is used.

### Claim 10 (depends on 5)

The process according to claim 5, characterized in that the conversion in step b) is performed at a temperature of 10° C. to 35° C.

### Claim 11 (depends on 5)

The process according to claim 5, characterized in that the mesylate of formula VI obtained in step b) is used for the ring closing step c) without isolation from the reaction mixture.

### Claim 12 (depends on 5)

The process according to claim 5, characterized in that in step c) lithium tert.-butoxide or lithium-bis(trimethylsilyl)amide is selected as organic base.

### Claim 13 (depends on 12)

The process according to claim 12, characterized in that lithium tert.-butoxide or lithium-bis(trimethylsilyl)amide is applied in an amount of 2.5 mol equivalents to 3.5 mol equivalents relating to one mol equivalent of the amine of formula III.

### Claim 14 (depends on 5)

The process according to claim 5, characterized in that the conversion in step c) is performed at a temperature of −20° C. to 10° C.

### Claim 15 (depends on 5)

The process according to claim 5, characterized in that for the deprotection in step d) a solvent selected from acetone, methyl ethyl ketone, acetonitrile or tetrahydrofuran or mixtures thereof, or water in admixture with acetone, methyl ethyl ketone, acetonitrile or tetrahydrofuran or mixtures thereof are used.

### Claim 16 (depends on 15)

The process according to claim 15, characterized in that acetone or tetrahydrofuran or mixtures thereof or water in admixture with acetone or tetrahydrofuran or mixtures thereof are used.

### Claim 17 (depends on 5)

The process according to claim 5, characterized in that the conversion in step d) is performed at a temperature of 35° C. to 66° C.

### Claim 18 (depends on 1)

The process according to claim 1, wherein the compound of formula I is (2S,3S,11bS)-1-(2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl)-4(S)-fluoromethyl-pyrrolidin-2-one dihydrochloride.

### Claim 19

A crystalline form of (2S,3S,11bS)-1-(2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl)-4(S)-fluoromethyl-pyrrolidin-2-one dihydrochloride characterized by a powder X-ray diffraction pattern obtained with a CuK□ radiation which comprises the following peaks: 6.0±0.2, 10.1±0.2, 12.1±0.2, 13.2±0.2, 14.5±0.2, 15.2±0.2, 15.5±0.2, 16.1±0.2, 16.4±0.2, 17.7±0.2, 19.5±0.2, 20.7±0.2, 21.6±0.2, 22.6±0.2, 27.3±0.2, 27.8±0.2 and 30.2±0.2 in 2θ (2Theta).

### Claim 20

A crystalline form of (2S,3S,11bS)-1-(2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl)-4(S)-fluoromethyl-pyrrolidin-2-one dihydrochloride characterized by an IR absorption spectrum having characteristic peaks expressed in cm−1 at approximately 3582 cm−1, 3440 cm−1, 3237 cm−1, 2726 cm−1, 2535 cm−1, 2477 cm−1, 1953 cm−1, 1681 cm−1, 1601 cm−1, 1575 cm−1, 1525 cm−1, 1491 cm−1, 1408 cm−1, 1308 cm−1, 1260 cm−1, 1225 cm−1, 1193 cm−1, 1145 cm−1, 1130 cm−1, 1096 cm−1, 1054 cm−1, 1000 cm−1, 967 cm−1, 946 cm−1, 879 cm−1, 844 cm−1, 808 cm−1, 768 cm−1 and 654 cm−1.

### Claim 21

A crystalline DMF solvate form of (2S,3S,11bS)-1-(2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl)-4(S)-fluoromethyl-pyrrolidin-2-one dihydrochloride characterized by a powder X-ray diffraction pattern obtained with a Cuk□ radiation which comprises the following peaks: 6.8±0.2, 12.5±0.2, 13.5±0.2, 15.1±0.2, 17.4±0.2, 18.1±0.2, 18.4±0.2, 24.3±0.2, 24.8±0.2, 25.3±0.2, 27.2±0.2, 27.9±0.2, 28.1±0.2, 29.9±0.2 and 30.7±0.2 in 2θ (2Theta).

### Claim 22

A crystalline DMF solvate form of (2S,3S,11bS)-1-(2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl)-4(S)-fluoromethyl-pyrrolidin-2-one dihydrochloride characterized by an IR absorption spectrum having characteristic peaks expressed in cm−1 at approximately 3480 cm−1, 3376 cm−1, 2706 cm−1, 2682 cm−1, 2610 cm−1, 2574 cm−1, 2532 cm−1, 2381 cm−1, 1684 cm−1, 1659 cm−1, 1622 cm−1, 1574 cm−1, 1528 cm−1, 1487 cm−1, 1410 cm−1, 1383 cm−1, 1310 cm−1, 1267 cm−1, 1251 cm−1, 1229 cm−1, 1192 cm−1, 1135 cm−1, 1107 cm−1, 998 cm−1, 988 cm−1, 930 cm−1, 900 cm−1, 841 cm−1, 767 cm−1, 680 cm−1, and 667 cm−1.

### Claim 23

Amorphous form of (2S,3S,11bS)-1-(2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-3-yl)-4(S)-fluoromethyl-pyrrolidin-2-one dihydrochloride characterized by an IR absorption spectrum having characteristic peaks expressed in cm−1 at approximately 3429 cm−1, 2507 cm−1, 1680 cm−1, 1612 cm−1, 1515 cm−1, 1310 cm−1, 1261 cm−1, 1246 cm−1, 1219 cm−1, 1127 cm−1, 994 cm−1, 964 cm−1, 945 cm−1, 888 cm−1, 860 cm−1, 842 cm−1, 767 cm−1, 685 cm−1 and 635 cm−1.
